Scoring systems for the assessment of individual risk of HCC development during long term treatment with NAs
|Score||Patients evaluated||Included parameters||Cut off |
|CU-HCC||Asian patients: 1005 in training and 424 in validation cohort||Age, albumin, bilirubin, HBV DNA, cirrhosis||5||97% NPV over 10 years|
|GAG-HCC||Asian patients (n=820)||Age, sex, HBV DNA, cirrhosis||101||99% NPV over 10 years|
|REACH-B||Asian non-cirrhotic patients: 3584 in trainings and 1505 validation cohort||Age, sex, ALT, HBV DNA, HBeAg status||8||98% NPV over 10 years|
|PAGE-B||European patients: 1325 in training and 490 in validation cohort||Age, sex, platelets||<6||100% NPV over up to 5 years|
Dr. D.Zeqiraj medical doctor at QKUK- Pristina, department of Infectious disease.